# Endocrinology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Johnny Cash (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML004-SYN
- Date: 2026-03-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ayesha Rahimi, MD
- Calendar frame: modern shifted

- Requested by: Gideon Hale, MD

## Reason for consultation

Type 2 diabetes above goal in a 71-year-old man with autonomic and peripheral neuropathy and orthostatic hypotension. Please confirm whether diabetic autonomic neuropathy explains his lightheadedness on standing, advise on treating it, and help choose add-on glucose-lowering therapy. **S**

## History

Mr. Cash is seen at the request of Dr. Hale, on the same day as his four-week diabetes check. Since the first visit he has taken metformin 1000 mg twice daily without stomach upset, and his fasting home glucose readings run 140 to 170 mg/dL, with none below 70 and no shakiness, sweating, or confusion. He stands up in stages, has raised the head of his bed, wears waist-high compression, and drinks about 2 liters a day. He is still lightheaded on standing most mornings and after meals, but he has had no further falls and no fainting. He has no nausea, diarrhea, early fullness, or difficulty passing urine. His feet are numb to the ankles, unchanged. He asks what is causing the lightheadedness. **S**

## Examination

| System | Finding |
|---|---|
| General | Alert and wry; walks in with a cane |
| Cardiovascular | Regular rhythm; blood pressure 150/84 mmHg lying, 142/78 mmHg seated, and 110/68 mmHg after three minutes standing, with heart rate 76 rising only to 80, and lightheadedness |
| Feet | Skin intact; no ulcers or calluses; monofilament and vibration sensation reduced to the ankles; pedal pulses present |
| Neurological | Reduced ankle reflexes; stocking sensory loss in both legs |

BP 142/78 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 95 kg; BMI 26.9 kg/m². All vital signs are synthetic.

## Data reviewed

The intake HbA1c, kidney function, urine albumin-creatinine ratio, vitamin B12, TSH, and hemoglobin; today's basic metabolic panel; the intake and today's lying, seated, and standing blood pressures and heart rates; and his home glucose log. Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.06 mg/dL; eGFR: 72 mL/min/1.73 m²; Glucose: 152 mg/dL (high). All results are synthetic.

## Assessment

1. **Neurogenic orthostatic hypotension from diabetic autonomic neuropathy** (I95.1). Systolic pressure falls 32 mmHg from sitting to standing while heart rate rises only 4 beats per minute, the same pattern as at intake: a neurogenic cause. With long-standing diabetes and length-dependent sensory loss, diabetic autonomic neuropathy explains it, and the earlier Shy-Drager label is not carried forward. Formal autonomic testing would not change treatment. He is still symptomatic on non-drug measures, and lying pressure of 150/84 mmHg allows a low dose of a pressor. **S**
2. **Type 2 diabetes with diabetic autonomic neuropathy** (E11.43). HbA1c 8.6 percent, above an individualized goal below 7.5 percent that suits his age, neuropathy, falls, and low vision. Autonomic neuropathy can blunt the warning signs of low glucose, so insulin and sulfonylureas are avoided. An SGLT2 inhibitor would add fluid loss to his orthostatic hypotension, and a GLP-1 receptor agonist's nausea, slowed stomach emptying, and weight loss are poorly tolerated with autonomic neuropathy; he has no atherosclerotic disease, heart failure, or kidney disease that would make either essential. Sitagliptin carries little risk of low glucose and does not lower blood pressure, and eGFR 72 allows the full dose. **S**
3. **Diabetic peripheral neuropathy with loss of protective sensation** (E11.42). No ulcer or pre-ulcerative lesion. Vitamin B12 286 pg/mL is low-normal on metformin and should be watched. **S**

## Recommendations

1. Start midodrine 2.5 mg on waking, at midday, and mid-afternoon, with the last dose at least four hours before bed. If he is still symptomatic and lying pressure allows, increase to 5 mg three times daily.
2. Continue staged standing, head-of-bed elevation, compression, and fluids.
3. Check lying, seated, and standing pressure at each visit to watch for high pressure lying down; avoid fludrocortisone, which raises lying pressure and lowers potassium.
4. No blood pressure medicine for the seated readings while standing pressure is low.
5. Start sitagliptin 100 mg daily and continue metformin 1000 mg twice daily.
6. HbA1c goal below 7.5 percent; HbA1c at the three-month review.
7. Avoid insulin and sulfonylureas.
8. Vitamin B12 periodically while on metformin.
9. Keep avoiding eye drops that slow the heart or lower blood pressure, such as timolol and brimonidine.

## Strengths and supports

- Supports: a family member who comes to visits and fills his pill organizer, and his church community **S**

## Communication

Discussed with Dr. Hale in person today; the patient agrees with the plan. **S**

## Follow-up

Primary care will manage titration and monitoring on the CMID schedule. Endocrinology will see him again if HbA1c stays above goal on two agents, if he has low glucose, or if orthostatic symptoms or falls continue despite midodrine. **S**

## Guideline basis

- Standards of Care in Diabetes—2025 (2025), American Diabetes Association
- CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026), Aether Forge
